Literature DB >> 1310239

Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production.

E N Cozza1, S Chiou, C E Gomez-Sanchez.   

Abstract

Endothelin-1 (ET-1) binds to specific receptors in cultured bovine adrenal glomerulosa cells and stimulates aldosterone secretion with a 50% effective concentration (EC50) of 300 +/- 80 pM (mean +/- SE). The relative stimulatory potency for ET-1 is significantly less than that of angiotensin II (ANG II). The incubation of calf zona glomerulosa cells in primary culture with ET-1 and ANG II resulted in a significant potentiation of ANG II effect on aldosterone secretion. The EC50 of ET-1 potentiation of ANG II-induced stimulation of aldosterone secretion was 40 +/- 5 pM (mean +/- SE, n = 4), which is lower than the EC50 for ET-1 stimulation of aldosterone secretion. Adrenocorticotropic hormone (ACTH) stimulation of aldosterone secretion, but not that of potassium, was also potentiated by ET-1, but to a lesser degree. ET-1 and ET-1-mediated potentiation of ANG II-stimulated aldosterone biosynthesis increased both the early and late pathways of aldosterone biosynthesis, but the potentiation was greater for the early pathway. Preincubation with ET-1 for at least 15 min, followed by extensive washing to remove bound ET-1, also resulted in persistent potentiation of ANG II-mediated aldosterone secretion. ET-2, sarafotoxin, and vasoactive intestinal contractor potentiation of ANG II action were very similar to that of ET-1. ET-3 and Big-ET-1 potentiated ANG II stimulation only at the highest doses tested and the proendothelin-(110-130) fragment was inactive. ET-1 potentiation of ANG II action is likely to be mediated through an ETB receptor subtype.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310239     DOI: 10.1152/ajpregu.1992.262.1.R85

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Clinical experience with endothelin receptor antagonists in chronic heart failure.

Authors:  A Seed; M P Love; J J McMurray
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Mechanisms of endothelin-1-induced MAP kinase activation in adrenal glomerulosa cells.

Authors:  Bukhtiar H Shah; Albert J Baukal; Hung-Dar Chen; Ali B Shah; Kevin J Catt
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

Review 3.  Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction.

Authors:  Keyur B Shah; Stephen S Gottlieb
Journal:  Curr Heart Fail Rep       Date:  2004-12

Review 4.  Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Authors:  Lowell Ling; Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

6.  Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex.

Authors:  G Rossi; G Albertin; A Belloni; L Zanin; M A Biasolo; T Prayer-Galetti; M Bader; G G Nussdorfer; G Palù; A C Pessina
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta.

Authors:  James M Luther; Zuofei Wang; Ji Ma; Natalia Makhanova; Hyung-Suk Kim; Nancy J Brown
Journal:  Endocrinology       Date:  2008-12-23       Impact factor: 4.736

Review 8.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.